# Study to Evaluate the Efficacy and Safety of Nizubaglustat (AZ-3102) in Patients With Gaucher Disease Type 3 (GD3)

> **NCT07715084** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Azafaros B.V.** · enrollment: 20 (estimated)

## Conditions studied

- Gaucher Disease Type 3

## Interventions

- **DRUG:** AZ-3102

## Key facts

- **NCT ID:** NCT07715084
- **Lead sponsor:** Azafaros B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-28
- **Primary completion:** 2028-01
- **Final completion:** 2029-07
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07715084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07715084, "Study to Evaluate the Efficacy and Safety of Nizubaglustat (AZ-3102) in Patients With Gaucher Disease Type 3 (GD3)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07715084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*